Lushang Freda Pharmaceutical Co.,Ltd. (SHA:600223)
China flag China · Delayed Price · Currency is CNY
7.27
-0.15 (-2.02%)
At close: Feb 13, 2026

SHA:600223 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Revenue
3,7383,9444,51112,65912,20113,423
Other Revenue
38.938.967.66292.87161.85192.08
3,7773,9834,57912,95112,36313,615
Revenue Growth (YoY)
-5.26%-13.02%-64.65%4.76%-9.20%32.33%
Cost of Revenue
1,8021,8912,45710,0259,38410,856
Gross Profit
1,9752,0912,1212,9262,9802,760
Selling, General & Admin
1,5741,6441,6681,6611,6281,172
Research & Development
179.03166.77153.36133.92118.7577.17
Other Operating Expenses
44.1540.1536.42539.39585.63747.88
Operating Expenses
1,8191,8771,8942,3502,3431,994
Operating Income
156.15214.71227.71575.66636.91765.96
Interest Expense
-7.57-22.12-94.75-400.97-112.32-91.2
Interest & Investment Income
117.94115.8259.29163.61239.56255.8
Currency Exchange Gain (Loss)
1.851.850.3212.59-1.14-2.44
Other Non Operating Income (Expenses)
-3.53-1.7-8-62.17-139.2-97.69
EBT Excluding Unusual Items
264.84308.55384.56288.73623.82830.43
Impairment of Goodwill
---1.85-4.74-3.98-
Gain (Loss) on Sale of Assets
-0.820.42-1.120.44-0.040.09
Asset Writedown
4.81-----0.93
Legal Settlements
------6.4
Other Unusual Items
35.937.3331.37-23.3723.9330.32
Pretax Income
304.73346.29412.96261.06643.73853.5
Income Tax Expense
39.4849.8546.82195.96249.93214.61
Earnings From Continuing Operations
265.25296.44366.1465.1393.8638.89
Minority Interest in Earnings
-51.14-52.92-62.75-19.64-31.9-0.22
Net Income
214.11243.53303.3945.46361.9638.67
Net Income to Common
214.11243.53303.3945.46361.9638.67
Net Income Growth
-9.47%-19.73%567.44%-87.44%-43.34%85.39%
Shares Outstanding (Basic)
1,0191,0151,0111,1361,005998
Shares Outstanding (Diluted)
1,0191,0151,0111,1361,0341,014
Shares Change (YoY)
2.90%0.34%-11.01%9.90%2.00%0.05%
EPS (Basic)
0.210.240.300.040.360.64
EPS (Diluted)
0.210.240.300.040.350.63
EPS Growth
-12.02%-20.00%650.00%-88.57%-44.44%85.29%
Free Cash Flow
78.6671.44262.79831.986,5674,291
Free Cash Flow Per Share
0.080.070.260.736.354.23
Dividend Per Share
0.0600.1100.1000.1100.1100.200
Dividend Growth
-60.00%10.00%-9.09%--45.00%81.82%
Gross Margin
52.29%52.51%46.33%22.59%24.10%20.27%
Operating Margin
4.13%5.39%4.97%4.45%5.15%5.63%
Profit Margin
5.67%6.12%6.63%0.35%2.93%4.69%
Free Cash Flow Margin
2.08%1.79%5.74%6.42%53.12%31.51%
EBITDA
218.18308.37363.55692.15729.53851.95
EBITDA Margin
5.78%7.74%7.94%5.34%5.90%6.26%
D&A For EBITDA
62.0393.66135.84116.4992.6285.99
EBIT
156.15214.71227.71575.66636.91765.96
EBIT Margin
4.13%5.39%4.97%4.45%5.15%5.63%
Effective Tax Rate
12.95%14.40%11.34%75.06%38.83%25.14%
Revenue as Reported
3,7773,9834,57912,95112,36313,615
Advertising Expenses
-811.13784.1705.36630.15388.03
Source: S&P Global Market Intelligence. Standard template. Financial Sources.